Evaluate Omnium

Transform your confidence levels 

Evaluate Omnium provides a complete, dynamic view of development risk and commercial return across all phases of the clinical lifecycle — including early-phase and privately-developed drugs not covered by analysts forecasts.

With product-specific data included Predicted Peak Sales, Probability of Technical and Regulatory Success (PTRS), R&D Costs, Net Present Value, Time-to-Peak and more, Evaluate Omnium makes it easier than ever quantify and compare risk and return across the full pipeline landscape.

Explore the video and other content below to see how Evaluate Omnium transforms asset screening and valuation, competitive intelligence, portfolio prioritisation and internal forecasting, then request your free trial today.

Hand holding test tube

Learn More: Predicted Peak Sales

80% of R&D drugs aren't covered by analyst forecasts until Phase III, so how can you make informed, objective decisions about a product's future in earlier phases?

Predicted Peak Sales analyses 25 years of market data and 4.3m data points to predict commercial potential from Phase I. It covers 99% of NMEs in our system, while delivering 53% more accuracy than consensus forecasts for early-stage drugs and comparable accuracy for late-stage drugs.

Watch the video to learn more about how Predicted Peak Sales delivers the coverage you need — with numbers you can trust.


All Data and Features Available in Evaluate Omnium

Success Rates

Predicts which in-house or competitor drugs are most likely to reach the market, so you can compare risk levels across products or indications. Includes product-specific probability of technical and regulatory success (PTRS), fully transparent risk audits and success rate benchmarks.
Request Your Free Trial

Development Timelines

Predicts when key development milestones will occur, so you can track progress against competitors or highlight products with first-in-class potential. Includes time-in-phase, launch date and market entry order predictions, as well as recruitment timeline benchmarks.
Request Your Free Trial

R&D Costs

Provides the industry’s first comprehensive clinical trial costing model, applying real-world data to over 50,000 trials, so you can better assess likely costs across the development cycle. Includes estimated, product-level trial costs for past and current clinical trials, future R&D cost predictions and industry benchmarks by indication.
Request Your Free Trial

Clinical Trials

Tracks and integrates clinical trials from three key industry sources alongside key commercial insights, so you can fully understand company development plans and pipelines.
Request Your Free Trial

Predictive Clinical Trial Design

Predicts the future patient enrolment needed to successfully complete clinical development, so you can determine trial resources needed, alongside historical benchmarks by phase and indication.
Request Your Free Trial

Clinical Outcomes

Aggregates and standardises clinical trial outcomes for indications and products so you can stay informed on trial results, updated daily and focused on the indication-specific endpoints most likely to lead to regulatory approval.
Request Your Free Trial 

Calendar of Events

Identifies and tracks critical product lifecycle and company events, such as trial initiations, regulatory decisions and financial results, so you can stay informed on key market catalysts or competitor activities.
Request Your Free Trial

NPV (Net Present Value) Analyzer

Calculates a product’s Net Present Value (NPV) using a interactive model based on discounted cash flow models to 2040 for over 6,000 products, with editable inputs so you can create custom models.
Request Your Free Trial

NPV by Indication

Extends Evaluate Omnium's NPV Analyzer model to the indication level, with increased granularity on inputs and cashflow by indication, improving your understanding of product value drivers.
Request Your Free Trial

Predicted Peak Sales

Delivers an independent, balanced view of asset potential with comprehensive coverage across all phases of the clinical lifecycle, including early-stage and privately-owned drugs, so you can identify the products with the greatest commercial potential. 
Request Your Free Trial

Market Dynamics

Provides time-to-peak analysis so you can better assess a drug’s market impact or improve product launch planning. Includes US time-to-peak benchmarks by indication, market exclusivity impact and time-to-peak values for historically launched drugs. 
Request Your Free Trial


Aggregates key pricing data, so you have easy access to consolidated, standardised US pack pricing for approved products, current cost-per-patient values for launched products and benchmarks for annual cost-per-patient by indication and technology. 
Request Your Free Trial

Market Access

Provides unique formulary access scores to help you identify the current market access position for products launched in the US, with benchmarks by EphMRA code, technology and mechanism of action.
Request Your Free Trial

Unmet Needs

Quantifies and compares the degree of unmet need across indications, so you can better focus portfolio investments on therapeutic areas that could have the greatest impact to patients.
Request Your Free Trial

Risk-Adjusted Peak Sales

Combines the improved accuracy of our Product Specific PTRS and Predicted Peak Sales analytics, so you have a single metric for forecasting the commercial potential of pharma assets across all phases of clinical development. 
Request Your Free Trial

Side-by-Side Comparisons

Combines Evaluate Omnium's risk and return data in unique, interactive visualisations, so you can quickly and efficiently compare products based on consistent, proven methodologies. 
Request Your Free Trial

Learn More: Product Specific PTRS

With 88% of novel drugs failing in clinical development, inaccurate risk assessments cost the industry billions in wasted R&D spending every year.

Evaluate Omnium's Product Specific PTRS analyses over 1.7m data points, 37,000 phase transitions and 26,000 drug programmes to predict a drug’s individual risk based on 50+ unique product attributes. As a result, it delivers 4 times greater accuracy when predicting which Phase I assets will reach the market, compared to industry average benchmarks.

Alongside historic success rates, phase progression probabilities and detailed risk audits, Product Specific PTRS provides the insight and context need to fully understand which drugs have the greatest potential to reach the market, so you can make more informed strategic choices.

Learn More: Visualising Risk and Return

With the range and scope of data available across Evaluate Omnium, it's never been easier to explore risk and return in a single, combined view. 

Evaluate Omnium's exclusive data visualisations allow you compare the Predicted Peak Sales and Product Specific PTRS for each product in the market landscape, so you can instantly determine which drugs have the best chance of market approval and success. In addition, the integrated data makes it easy to drill down and understand the unique factors driving each product's predictions.

Learn More: NPV Analyzer and NPV by Indication

The average cost of bringing a new drug to market can reach $1.6bn, so it's critical to understand whether the potential value is worth the investment.

Evaluate Omnium's Net Present Value (NPV) Analyzer offers a detailed, standardised view of the current NPV for over 6,000 products, based on discounted cash flow models to 2040. Fully transparent and interactive, you can quickly view the data inputs, or edit to create custom predictive models.

NPV by Indication adds another level of granularity, extending the NPV Analyzer model to the indication level for improved understanding of product value drivers. 


Enquire about Evaluate Omnium

Risk and return combined

Evaluate Omnium’s proprietary functionality and analytics, many of which are brand new to the market, cover the full product lifecycle. By bringing together the full depth and breadth of Evaluate’s unrivalled risk and return data in a single product, Evaluate Omnium provides a more accurate, impartial and timely view of pharma asset potential.